Image 4_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 6_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 3_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Table 1_Diverging trends in the global burden of ischemic heart disease attributable to non-optimal temperatures: a historical analysis (1990–2021) and 2050 projections.docx by Zehao Jin (11408687)

“…In addition, temporal trend analysis was conducted using joinpoint regression to identify significant inflection points and calculate the annual percent change (APC) estimates. …”

Data Sheet 1_Diverging trends in the global burden of ischemic heart disease attributable to non-optimal temperatures: a historical analysis (1990–2021) and 2050 projections.csv by Zehao Jin (11408687)

“…In addition, temporal trend analysis was conducted using joinpoint regression to identify significant inflection points and calculate the annual percent change (APC) estimates. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

DataSheet1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.pdf by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Comparison of the trend of people’s perceptions and the climatic trends (social data: Quantitative data: Household survey (n = 660); qualitative data: Focus group discussions (n =... by Parbati Phuyal (8687400)

“…Depending on the perception, the presence of a trend (yes, no, unclear/mixed) or a trend direction (increase, decrease, unclear) is given. Significance of each data type is presented in detail in Figs <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0317786#pone.0317786.g002" target="_blank">2</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0317786#pone.0317786.g005" target="_blank">5</a>. …”

SERCA is required for Ca²+ transients at E5.5. by Matthew J. Stower (22379321)

“…DMSO treated embryos had a significant decrease in transients (one-way ANOVA, <i>p</i> ≤ 0.001, followed by Tukey’s HSD Test; baseline vs. 30 min DMSO <i>p</i> > 0.05), but thapsigargin almost completely abolished transients to a significant effect (one-way ANOVA, <i>p</i> ≤ 0.001, followed by Tukey’s HSD Test, baseline vs. 30 min 10 nM thapsigargin <i>p</i> ≤ 0.001), that was significantly lower than DMSO controls (one-way ANOVA, <i>p</i> ≤ 0.001, followed by Tukey’s HSD Test, 30 min DMSO vs. 30 min 10 nM thapsigargin: <i>p</i> ≤ 0.001). …”

Image 1_Elevated thiamine level is associated with activating interaction between HIF-1α and SLC19A3 in experimental myopic guinea pigs.jpeg by Zhongyu Ma (12275357)

“…</p>Results<p>Compared with the normal control (NC) group, the LIM group guinea pigs showed a significant increase in axial length and decrease in refractive error, as well as a thinning of choroidal thickness and loosening of tissue structure. …”

The impact of excessive DNA amounts used for bisulfite conversion on the amplification efficiency and the methylation level of <i>LINE-1</i> and <i>Alu</i>. by Trang Thi Quynh Tran (20485595)

“…(<b>D, E</b>) An increase in methylation level of <i>LINE-1</i> (D) and <i>Alu</i> (E) was associated with a decrease in DNA input for bisulfite conversion. …”

ROC analysis to mark selectivity results in mostly mixed-selective units. by Thomas S. Wierda (22404198)

“…The large number of mixed selective units also results in a significant decrease in accuracy when these neurons are targeted as compared to <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1013559#pcbi.1013559.g006" target="_blank">Fig 6c</a> where there was no significant effect visible after targeting mixed selective units, likely because there were less mixed selective units present. …”

Supplementary file 1_Case Report: A case of reversible tracheal diameter Mounier-Kuhn syndrome and literature review.docx by Lu-xia Kong (21191087)

“…We encountered an 81-year-old male MKS patient whose diagnosis was delayed, and subsequently experienced a significant decrease in tracheal diameter post-diagnosis, marking the first documented case of reversible tracheal diameter in MKS patients. …”